Drug Trial Radar · NCT06058377
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,680
Planned (sponsor's estimate)
Start
Nov 27, 2023
Primary completion
May 31, 2032
Study completion May 31, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo optional collection of tissue and/or blood
CyclophosphamideDrug
Given IV
DoxorubicinDrug
Given IV
DurvalumabBiological
Given IV
Genetic TestingOther
Undergo MammaPrint testing
MammographyProcedure
Undergo mammography
PaclitaxelDrug
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Breast cancer event-free survival (BC-EFS)Time frame: Up to 10 years after completion of study treatment
Locations
565 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Katmai Oncology Group
Anchorage, Alaska · Recruiting
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Memorial Medical Center
Modesto, California · Recruiting
City of Hope Newport Beach
Newport Beach, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Desert Regional Medical Center
Palm Springs, California · Recruiting
Palo Alto Medical Foundation Health Care
Palo Alto, California · Recruiting
Huntington Memorial Hospital
Pasadena, California · Recruiting
Sutter Roseville Medical Center
Roseville, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
SWOG
Sacramento, California · Recruiting
Zuckerberg San Francisco General Hospital
San Francisco, California · Active not recruiting
California Pacific Medical Center-Pacific Campus
San Francisco, California · Recruiting
Mills Health Center
San Mateo, California · Recruiting
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California · Recruiting
Saint John's Cancer Institute
Santa Monica, California · Recruiting
Providence Medical Foundation - Santa Rosa
Santa Rosa, California · Recruiting
Sutter Pacific Medical Foundation
Santa Rosa, California · Recruiting
Providence Santa Rosa Memorial Hospital
Santa Rosa, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Recruiting
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California · Recruiting
Showing 40 of 565 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.